Publication:
Impact of Eculizumab on Reported Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study

Simple item page
dc.contributor.authorBerthele, A.
dc.contributor.authorPittock, S. J.
dc.contributor.authorFujihara, K.
dc.contributor.authorKim, H. J.
dc.contributor.authorLevy, M.
dc.contributor.authorPalace, J.
dc.contributor.authorWingerchuk, D. M.
dc.contributor.authorIDNakashima, Ichiro/0000-0002-2612-8948
dc.date.accessioned2020-06-21T12:26:00Z
dc.date.available2020-06-21T12:26:00Z
dc.date.issued2019
dc.departmentOMÜen_US
dc.department-temp[Berthele, A.] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, Munich, Germany -- [Pittock, S. J.] Mayo Clin, Dept Neurol, Rochester, MN USA -- [Fujihara, K. -- Nakashima, I.] Tohoku Univ, Grad Sch Med, Dept Neurol, Sendai, Miyagi, Japan -- [Fujihara, K.] Fukushima Med Univ, Sch Med, Dept Multiple Sclerosis Therapeut, Fukushima, Japan -- [Fujihara, K.] Southern TOHOKU Res Inst Neurosci STRINS, MS & NMO Ctr, Koriyama, Fukushima, Japan -- [Kim, H. J.] Natl Canc Ctr, Res Inst & Hosp, Dept Neurol, Goyang, South Koreaen_US
dc.description35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDENen_US
dc.description.abstract…en_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltden_US
dc.description.sponsorshipAlexion PharmaceuticalsFukuda Foundation for Medical TechnologyKayamori FoundationKayamori Foundation of Informational Science AdvancementSENSHIN Medical Research FoundationSasagawa Scientific Research GrantMukai Science and Technology Foundationen_US
dc.description.sponsorshipThis trial was supported by Alexion Pharmaceuticals. Dr Berthele reports compensations for clinical trials received by his institution from Alexion Pharmaceuticals, Biogen, Novartis Pharmaceuticals, Roche, Sanofi Genzyme, Teva Pharmaceuticals, and personal fees and non-financial support from Bayer Healthcare, Biogen, Merck Serono, Mylan, Novartis Pharmaceuticals, Roche, and Sanofi Genzyme.en_US
dc.identifier.endpage295en_US
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.startpage294en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/10622
dc.identifier.volume25en_US
dc.identifier.wosWOS:000485303101168
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleImpact of Eculizumab on Reported Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Studyen_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu